Ywhab Antibody

What is YWHAB protein and why is it significant in cancer research?

YWHAB (14-3-3 Beta) belongs to the 14-3-3 family of proteins that mediate signal transduction through phosphoserine/phosphothreonine binding interactions. YWHAB has emerged as a significant protein in cancer research due to its elevated expression in multiple cancer types, particularly breast cancer. Recent studies have demonstrated that YWHAB RNA and protein expression are significantly higher in aggressive breast cancer cell lines compared to normal cells . YWHAB plays crucial roles in cell migration, proliferation, and epithelial-to-mesenchymal transition (EMT), making it both a potential therapeutic target and biomarker for cancer progression .

What are the common applications of YWHAB antibodies in research?

YWHAB antibodies are versatile research tools employed across multiple experimental techniques:

• Western Immunoblotting: For quantitative protein expression analysis using nitrocellulose membranes with primary antibodies (typically 1:500 dilution for anti-14-3-3-beta)

• In-Cell Immunoblotting: For cellular protein detection in fixed cells (using 1:200 dilution of anti-YWHAB antibodies)

• Immunocytochemistry: For subcellular localization studies (1:400 dilution of anti-14-3-3-beta antibodies)

• Immunohistochemical Analysis: For examining protein expression in tissue samples, particularly in cancer tissues such as rectum and endometrial cancers

• Co-immunoprecipitation: For detecting protein-protein interactions (e.g., YWHAB interaction with PIK3R2)

What are the optimal conditions for YWHAB knockdown experiments?

For effective YWHAB knockdown in cancer cell lines, researchers have successfully employed siRNA transfection with the following methodological considerations:

• Transfection Protocol: PolyPlus INTERFERin siRNA/miRNA transfection kit using 1 nM siRNA concentration has demonstrated effective knockdown

• Control Conditions: Include scrambled siRNA (e.g., Ref# 9914G7) as negative control

• Knockdown Validation: Confirm knockdown efficiency at both RNA level (qPCR, target 80% reduction) and protein level (Western blot, target 40-50% reduction)

• Timing for Functional Assays: Conduct functional assays 24 hours post-knockdown for optimal results

• Cell Type Considerations: Knockdown efficiency may vary by cell type; HER2-enriched cell lines like SKBR3 show lower knockdown efficiency (10-15%) compared to other breast cancer cell lines (40-50%)

How should researchers optimize Western blot protocols for YWHAB detection?

For optimal YWHAB detection via Western blotting, researchers should follow these methodological guidelines:

• Protein Extraction: Use 10X Cell Lysis Buffer with Protein Phosphatase Inhibitor

• Loading Amount: Load 20-40μg of protein per lane

• Gel Concentration: 10% polyacrylamide gel works effectively for YWHAB separation

• Primary Antibody: Anti-14-3-3-beta (1:500 dilution, Santa Cruz Biotechnology, Cat#sc-25276)

• Incubation Conditions: Overnight incubation at 4°C

• Secondary Antibody: AzureSpectra 700 anti-mouse (1:10000)

• Loading Controls: Alpha-tubulin (1:1000) or beta-actin (1:5000)

What controls and validations are necessary for YWHAB antibody experiments?

To ensure experimental rigor when working with YWHAB antibodies, researchers should implement the following controls and validations:

• Positive Controls: Include cells known to express high levels of YWHAB (e.g., aggressive breast cancer cell lines such as MCF7-miR526b)

• Negative Controls:

  • Primary antibody omission controls

  • Isotype controls

  • Non-expressing or low-expressing cell lines

• Knockdown Validation: Confirm specificity by demonstrating reduced signal in YWHAB knockdown samples

• Multiple Detection Methods: Validate findings using complementary techniques (e.g., Western blot, ICC, IHC)

• Antibody Validation: Verify antibody specificity through immunoprecipitation followed by mass spectrometry

How can YWHAB antibodies be used to investigate protein-protein interactions in signaling pathways?

YWHAB antibodies are valuable tools for investigating protein-protein interactions within complex signaling pathways:

• Co-immunoprecipitation (Co-IP):

  • Primary approach for identifying YWHAB binding partners

  • Example: YWHAB and PIK3R2 interaction in colon cancer cells

  • Protocol: Lysate pre-clearing, antibody immobilization (2-5μg anti-YWHAB), overnight incubation, and protein complex elution

• Proximity Ligation Assays (PLA):

  • For visualizing protein interactions within intact cells

  • Requires specific anti-YWHAB antibody pairs (typically mouse and rabbit origin)

  • Provides spatial information about interaction sites within cells

• FRET/BRET Analysis:

  • For studying dynamic interactions in living cells

  • Requires conjugation of fluorophores to anti-YWHAB antibodies or expression of fluorophore-tagged YWHAB

• Signaling Pathway Investigation:

  • YWHAB antibodies have been instrumental in elucidating the role of YWHAB in the PI3K/AKT signaling pathway

  • Researchers can use phospho-specific antibodies alongside YWHAB antibodies to track pathway activation

What are the methodological considerations for using YWHAB antibodies in biomarker studies?

When employing YWHAB antibodies for biomarker development and validation, researchers should consider these methodological approaches:

• Tissue Microarray Analysis:

  • Enables high-throughput evaluation of YWHAB expression across multiple tumor samples

  • Requires optimization of antibody dilution (typically 1:200-1:500)

  • Include positive and negative controls on each array

• Liquid Biopsy Applications:

  • YWHAB has shown potential as a blood biomarker when combined with pri-miR-526b (AUC of 0.711, p = 0.032)

  • Blood plasma protocols require antibody validation in both tumor tissue and circulating biomarkers

• Combinatorial Biomarker Panels:

  • Single YWHAB detection has limitations as a blood biomarker

  • Sensitivity improves when combined with other markers like pri-miR-526b

  • Statistical validation requires larger sample sizes (n>100) for clinical relevance

• ROC Curve Analysis:

  • Essential for determining diagnostic potential

  • YWHAB as a tumor marker shows AUC of 0.7340 (p = 0.0012)

  • Statistical validation through multi-cohort studies is recommended

How can YWHAB antibodies be utilized in immunohistochemical studies of different cancer types?

YWHAB antibodies have demonstrated utility across various cancer types in immunohistochemical analyses:

• Optimization by Cancer Type:

  • Breast cancer: DAB staining with hematoxylin counterstain

  • Rectum cancer: Mouse monoclonal antibodies with DAB staining

  • Endometrial cancer: Mouse monoclonal antibodies with DAB staining

  • Colon cancer: YWHAB antibodies for assessing expression in relation to cell cycle regulation

• Scoring Systems:

  • Semi-quantitative scoring based on staining intensity (0-3+)

  • Percentage of positive cells (0-100%)

  • Combined scores for statistical analysis

• Correlation with Clinical Parameters:

  • YWHAB expression correlates with advanced tumor stages

  • High expression links to poor patient survival in breast cancer

  • Analysis across hormonal subtypes shows expression in all breast cancer subtypes

What are common challenges in YWHAB antibody-based experiments and how can they be addressed?

Researchers frequently encounter these challenges when working with YWHAB antibodies:

How should researchers interpret conflicting YWHAB expression data between different experimental methods?

When encountering discrepancies in YWHAB expression between different techniques:

• Methodological Considerations:

  • Western blotting quantifies total protein expression

  • IHC/ICC provides spatial information but is semi-quantitative

  • qPCR measures mRNA which may not correlate with protein levels

• Resolution Approaches:

  • Employ multiple antibodies targeting different YWHAB epitopes

  • Validate findings across multiple cell lines or patient samples

  • Use complementary techniques (e.g., mass spectrometry) for confirmation

• Data Integration:

  • When tissue and blood plasma data conflict (as seen in YWHAB biomarker studies), prioritize larger datasets

  • Consider statistical power and sample size differences

  • Account for context-specific expression patterns (e.g., YWHAB showed limited sensitivity as a blood biomarker despite significant tumor expression)

How does YWHAB knockdown affect cell migration in different cancer types?

YWHAB knockdown has demonstrated significant effects on cancer cell migration across multiple models:

• Breast Cancer:

  • Knockdown inhibits migration in all breast cancer subtypes, including triple-negative breast cancer

  • Migration assays show reduced wound healing rates after YWHAB siRNA treatment

  • Effect is independent of hormone receptor status

• Colon Cancer:

  • YWHAB depletion promotes cell apoptosis while inhibiting proliferation

  • Affects G1-S cell-cycle transition regulators including cyclin D1

  • Influences apoptosis marker proteins Bcl2 and Bax

• Methodological Approach for Migration Studies:

  • Use Mitomycin C (10 μg/mL for 2-3 hours) to inhibit cell proliferation

  • Create standardized scratches and capture images at regular intervals (0-24 hours)

  • Measure wound width at multiple points and calculate healing rate using the formula:
    (0-hour distance - interval distance) / (0-hour distance) × 100%

What is the relationship between miRNAs and YWHAB, and how can this be investigated?

The emerging relationship between microRNAs and YWHAB regulation offers a promising research direction:

• Established Relationships:

  • YWHAB was found in the secretome of miR-526b and miR-655 overexpressed breast cancer cells

  • Combined with pri-miR-526b, YWHAB shows potential as a blood biomarker (AUC 0.711, p=0.032)

• Investigation Methods:

  • miRNA overexpression studies in cell lines

  • qPCR validation of YWHAB expression following miRNA modulation

  • Luciferase reporter assays to confirm direct miRNA binding to YWHAB

• Functional Studies:

  • Compare phenotypes between miRNA overexpression and YWHAB knockdown

  • Rescue experiments by expressing YWHAB lacking miRNA binding sites

  • Investigate downstream molecular pathways affected by both miRNA and YWHAB

• Clinical Correlation:

  • Analyze paired miRNA and YWHAB expression in patient samples

  • Stratify patient outcomes based on combinatorial expression patterns

What are emerging applications of YWHAB antibodies in cancer therapeutic development?

YWHAB antibodies are increasingly valuable for therapeutic development in several ways:

• Target Validation:

  • YWHAB knockdown inhibits migration, proliferation, and EMT across all subtypes of breast cancer, including triple-negative breast cancer

  • This validates YWHAB as a potential therapeutic target

• Companion Diagnostics:

  • YWHAB antibodies can help identify patients likely to respond to YWHAB-targeted therapies

  • IHC-based patient stratification using standardized scoring systems

• Therapeutic Antibody Development:

  • Characterizing epitopes for potential therapeutic antibody development

  • Targeting YWHAB-dependent protein-protein interactions

• Response Monitoring:

  • Using YWHAB antibodies to monitor treatment response in preclinical models

  • Potential circulating biomarker for treatment efficacy when combined with other markers

How can researchers best validate YWHAB as a combination biomarker for early cancer detection?

For validating YWHAB in combination biomarker panels:

• Multi-cohort Validation Studies:

  • The combination of YWHAB with pri-miR-526b showed AUC of 0.711 (p=0.032) in preliminary studies

  • Validation requires larger sample sizes (>200) across diverse populations

  • Include multiple cancer stages with emphasis on early detection potential

• Standardized Detection Protocols:

  • Develop consistent blood collection and processing protocols

  • Optimize antibody-based detection methods (ELISA, multiplex assays)

  • Establish normal reference ranges across different demographics

• Machine Learning Integration:

  • Apply AI algorithms to optimize biomarker combinations

  • Develop risk prediction models incorporating clinical data

  • Compare against existing biomarkers for incremental value assessment

• Prospective Clinical Studies:

  • Design prospective studies with predefined endpoints

  • Calculate sensitivity, specificity, and positive/negative predictive values

  • Determine lead-time advantage for earlier detection